Skip to main content

drug discovery Archives

Current cancer drug discovery method flawed: VUMC study

May. 5, 2016—The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods.

Read more


Putting schizophrenia to bed

Mar. 21, 2016—A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.

Read more


Vanderbilt, Ono Pharmaceutical sign drug discovery agreement

Dec. 10, 2015—Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement.

Read more


Rational design of novel antifungals

Oct. 7, 2015—Structural and molecular details of an anti-fungal target's interaction with inhibitors suggest ways to design better treatments for fungal infections.

Read more


Collaboration seeks to develop new therapies for bone, other diseases

Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

Read more


Drug signaling networks

Jul. 15, 2015—Vanderbilt investigators have developed a new algorithm to understand the networks of signaling molecules that control drug action.

Read more


New strategy to combat HIV

Jun. 12, 2015—Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.

Read more


Grant spurs schizophrenia research

Feb. 12, 2015—Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.

Read more


Targeting HIV’s “cap”

Feb. 10, 2015—New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target.

Read more


Life’s extremists may be an untapped source of antibacterial drugs

Nov. 21, 2014—A family of single-celled organisms that thrive in environments too extreme for most other species to survive may be an untapped source of new antibacterial drugs.

Read more


Receptor discovery shines new light on appetite regulation

Nov. 20, 2014—A receptor in the brain that regulates appetite and body weight has now been found in L cells, key regulatory cells in the gut, providing the pharmaceutical industry with a novel drug target for both obesity and diabetes, a Vanderbilt University-led research team reported this week.

Read more


Lung cancer study reveals new drug combination targets

Sep. 4, 2014—A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.

Read more


Page 2 of 41234

Upcoming Events

MORE EVENTS »